Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $14.70 USD
Change Today -0.84 / -5.41%
Volume 825.5K
SGMO On Other Exchanges
SGMO is not on other exchanges.
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

sangamo biosciences inc (SGMO) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - $19.25
52 Week Low
10/13/14 - $9.39
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

sangamo biosciences inc (SGMO) Related Businessweek News

No Related Businessweek News Found

sangamo biosciences inc (SGMO) Details

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for unmet medical needs in the United States. Its zinc finger DNA-binding proteins (ZFPs) could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways for genome editing and gene regulation; and ZFP transcription factors (ZFP TFs) proteins could be used to turn genes on or off. The company’s principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops CERE-110 that is in Phase II clinical trial for the treatment of Alzheimer’s disease. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, huntington’s disease, and hemoglobinopathies; and proprietary programs in the areas of lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including various immunodeficiencies, as well as central nervous system disorders and cancer immunotherapy. The company has collaboration and license agreements with Shire International GmbH and Biogen Idec Inc.; and strategic partnerships with Sigma-Aldrich Corporation, Dow AgroSciences, LLC, Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.

102 Employees
Last Reported Date: 02/25/15
Founded in 1995

sangamo biosciences inc (SGMO) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $640.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $400.0K
Chief Medical Officer and Vice President of T...
Total Annual Compensation: $437.5K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $385.0K
Executive Vice President of Research and Deve...
Total Annual Compensation: $453.5K
Compensation as of Fiscal Year 2013.

sangamo biosciences inc (SGMO) Key Developments

Sangamo Biosciences Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Revenue Guidance for the Fiscal Year 2015

Sangamo Biosciences Inc. reported consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $13,491,000 against $8,116,000 a year ago. Loss from operations was $6,221,000 against $7,611,000 a year ago. Loss before taxes was $6,067,000 against $7,572,000 a year ago. Net loss was $5,319,000 or $0.08 per share basic and diluted against $7,572,000 or $0.12 per share basic and diluted a year ago. The company expects that revenues will be in the range of $60 million to $70 million for fiscal year 2015.

Sangamo Biosciences Inc. to Report Q1, 2015 Results on Apr 22, 2015

Sangamo Biosciences Inc. announced that they will report Q1, 2015 results at 5:00 PM, US Eastern Standard Time on Apr 22, 2015

Sangamo Biosciences Inc., Q1 2015 Earnings Call, Apr 22, 2015

Sangamo Biosciences Inc., Q1 2015 Earnings Call, Apr 22, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGMO:US $14.70 USD -0.84

SGMO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bluebird Bio Inc $136.26 USD -3.82
Fibrocell Science Inc $3.87 USD +0.12
View Industry Companies

Industry Analysis


Industry Average

Valuation SGMO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.9x
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANGAMO BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at